GlobeNewswire

BIMobject AB: Notice to attend Extraordinary General Meeting on September 5, 2018. Patrick Söderlund and Hjalmar Winbladh proposed as new Board Members in BIMobject AB. A split 2:1 is proposed.

Dela
Shareholders representing approximately 49 percent of the votes in BIMobject AB have announced that they propose that Hjalmar Winbladh and Patrick Söderlund are appointed new Board Members at an Extraordinary General Meeting to be held on Wednesday September 5, 2018. Ben O'Donnell resigns as Board Member in connection with the Extraordinary General Meeting. The Board will thereafter be composed of Stefan Larsson (CEO), Anders Wilhjelm (Chairman), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh and Patrick Söderlund. Furthermore, a change in remuneration to the Board is proposed. The new Board fee totals SEK 800,000 and is to be divided between the Chairman and Söderlund with SEK 400,000 each. The board also proposes that the General Meeting resolves to split the company's shares 2:1.

Patrick Söderlund, born in 1973 and a Swedish citizen, is Chief Design Officer and Executive Vice President at Electronic Arts. In his present role he manages the development of technology innovation and drives Electronic Art's marketing teams. Previously, Patrick led EA Worldwide Studios, the studio teams behind games such as Need for Speed and The Sims. He also founded Refraction Games, later acquired by DICE, which in the early 2000s created and developed the Battlefield game series. Patrick will leave his employment at Electronic Arts later this year.

Hjalmar Winbladh, born in 1968 and a Swedish citizen, is Partner at EQT Partners and Head of the EQT Ventures advisory team at the EQT Ventures fund (EQT Ventures). Prior to founding EQT Ventures, Hjalmar founded IT company Sendit AB, later acquired by Microsoft. Additionally, Hjalmar has founded and co-founded companies such as Wrapp, Rebtel, and Epidemic Sound. At EQT Ventures, he works with portfolio companies such as Wolt, Codacy, Home and Peltarion. Hjalmar has attended Stockholm University and INSEAD.

"I've been in game development since the 90s, and I've seen the industry go from analog and offline, to digital and online with millions of users active at the same time. Having extensive experience from one of the world's largest gaming companies - Electronic Arts - I look forward to addressing some of the challenges that digital companies often encounter: scalability, payment solutions and an active community. Through my construction company Ortalis Group, I have also seen the challenges that manufacturers, property managers, and construction companies face on a daily basis. For that reason, I'm very enthusiastic about working with BIMobject's Board and using my experience to accelerate digitalization in relatively analog industries" says Patrick Söderlund.

"Patrick has unique experience in scaling up digital projects from their initial phases to becoming world-leading products. With his expertise, we will continue to build BIMobject into a global winner, where the whole world's building, construction, and interior design products will be featured on our platforms. Additionally, Hjalmar's extensive knowledge in managing tech companies will help us to continue to revolutionize industries that haven't fully adopted digitalization yet" says Stefan Larsson, founder and CEO of BIMobject.

For complete notice, please see below.

For more information, please contact:
Stefan Hansson - CFO
Tel: +46 40 685 29 00
Email:info@bimobject.com
About BIMobject AB
BIMobject is a leading global IT company at the forefront of digitalisation of the construction industry. BIMobject offers a cloud-based platform, with over 1,000 manufacturers providing digital product information. Around the cloud-based platform, which currently has over 850,000 users, BIMobject offers a number of solutions aimed at property owners, construction companies and the trade sector. BIMobject, founded in 2011, operates in 20 countries and has over 200 employees. Revenue for 2017 amounted to SEK 84 million. BIMobject's shares are traded on Nasdaq First North under the ticker: BIM. BIMobject's Certified Advisor is FNCA Sweden AB.www.bimobject.com

This is an English version of an original Swedish press release communicated by BIMobject AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply.

Notice of extraordinary general meeting of BIMobject

The shareholders of BIMobject AB (publ) are summoned to an extraordinary general meeting on Wednesday 5 September 2018 at 10 am at Studio, Nordenskiöldsgatan 24, 2nd floor, in Malmö, Sweden.

Participation and notification
Shareholders who wish to participate in the meeting shall be recorded as shareholder in the share register maintained by Euroclear Sweden AB on Thursday 30 August 2018, and notify the company of their intention to participate no later than on Thursday 30 August 2018, in writing to BIMobject AB, c/o Studio, Nordenskiöldsgatan 24, SE-211 19 Malmö, Sweden. Such notification can also be made by telephone +46 (0)40-685 29 00 or by e-mail bolagsstamma@bimobject.com. The notification shall include name, personal/corporate identity number, number of shares held, address, telephone number (daytime) as well as, when applicable, information about representatives or assistants (not more than two).

Nominee registered shares
Shareholders whose shares are registered in the name of a nominee, such as a bank or other securities institution, must re-register their shares in their own name with Euroclear Sweden AB in order to be entitled to participate in the meeting. Such registration, which may be temporary, must be duly effected on Thursday 30 August 2018, which means that a shareholder that wishes such registration must notify its nominee thereof well in advance of this date.

Proxy etc.
If a shareholder is represented by a proxy at the meeting, such proxy shall present a written and dated power of attorney at the meeting. The power of attorney may not be older than one year, provided that a longer validity period (however not more than five years) is stated in the power of attorney. If the power of attorney is issued on behalf of a legal entity, the proxy shall also present a certificate of registration or equivalent document for such legal entity. In order to facilitate the entrance to the meeting, a copy of the power of attorney and other documents of authorization should be included in the notification to the meeting. A proxy form is available at the company's website, www.bimobject.com, and is sent to shareholders who so request and state their address.

Number of shares and votes
The number of shares and votes of the company amounts to 59,474,842 as of the date of this notice. The company holds no treasury shares.

Proposed agenda
1. Opening of the meeting
2. Appointment of chairman of the meeting
3. Preparation and approval of voting list
4. Approval of the agenda
5. Appointment of one or two persons to verify the minutes
6. Determination of whether the meeting has been duly convened
7. Determination of number and appointment of board members
8. Determination of fees to the board
9. The board's proposal on share split
10.  Closure of the meeting

Appointment of board members (item 7)
Shareholders representing approximately 49 percent of the votes in the company have notified that they propose that the general meeting resolves (i) that the board shall be composed of six ordinary members, without deputies, and (ii) to appoint Hjalmar Winbladh and Patrick Söderlund as new board members for the time until the end of the next annual general meeting. Ben O'Donnell will be leaving his position as board member in connection with the general meeting. The board will thereafter be composed of Stefan Larsson, Anders Wilhjelm (chairman), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh and Patrick Söderlund.

Hjalmar Winbladh, born 1968 and Swedish citizen, is Partner at EQT Partners and Head of the EQT Ventures advisory team at the EQT Ventures fund (EQT Ventures). Before the foundation of EQT Ventures, Hjalmar founded the IT-company Sendit AB, which subsequently was acquired by Microsoft. Hjalmar has also founded and co-founded companies such as Wrapp, Rebtel and Epidemic Sound. At EQT Ventures, Hjalmar is working with portfolio companies such as Wolt, Codacy, Home and Peltarion. Hjalmar is educated at the University of Stockholm and INSEAD.

Patrick Söderlund, born 1973 and Swedish citizen, is Chief Design Officer and Executive Vice President at Electronic Arts. In that role, he manages the development of the company's technical innovations and the company's marketing team. Patrick was previously head of EA Worldwide Studios, the company behind the gaming series Need for Speed and The Sims. He also founded Refraction Games, later acquired by DICE, which in the early 2000's created and developed the Battlefield series. Patrick will leave his employment at Electronic Arts later this year.

Board fee (item 8)
Shareholders representing approximately 49 percent of the votes in the company have notified that they propose that fees to the board shall be paid with in total SEK 800,000, whereof SEK 400,000 shall be paid to the chairman of the board and SEK 400,000 shall be paid to Patrick Söderlund, thereby amending the resolution by the annual general meeting. It is proposed that no fee shall be paid to the other board members.

Share split (item 9)
The board proposes that the general meeting resolves to split the company's shares 2:1, whereby the existing 59,474,842 shares are split into 118,949,684 shares with a new quota value of SEK 0.011.

Documentation etc.
The board's complete proposal and supporting documentation will be held available at the company's offices, Nordenskiöldsgatan 24 in Malmö, Sweden, and on the company's website, www.bimobject.com, no later than two weeks prior to the meeting and will be sent to shareholders who so request and state their address.

The shareholders are reminded of their right to request information in accordance with chapter 7, section 32 of the Swedish Companies Act.

Processing of personal data
For information on how your personal data is processed in connection with the general meeting, refer to the company's integration policy (Sw.) which is available on the company's website, www.bimobject.com.

Malmö, Sweden, in August 2018
BIMobject AB (publ)
The Board of Directors via Chairman Wilhjelm




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BIMobject AB via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum